Cargando…

Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer

INTRODUCTION: Individual prediction of tumour behaviour based on molecular markers may refine adjuvant treatment strategies in endometrial cancer (EC). As these molecular alterations are determined in a small tumour fraction, high intratumour heterogeneity may interfere with correct risk prediction....

Descripción completa

Detalles Bibliográficos
Autores principales:	van Esterik, Manouk, Van Gool, Inge C., de Kroon, Cor D., Nout, Remi A., Creutzberg, Carien L., Smit, Vincent T.H.B.M., Bosse, Tjalling, Stelloo, Ellen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421949/ https://www.ncbi.nlm.nih.gov/pubmed/28424422 http://dx.doi.org/10.18632/oncotarget.16067

Ejemplares similares

Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors
por: Wortman, Bastiaan G., et al.
Publicado: (2019)

Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer
por: Stelloo, Ellen, et al.
Publicado: (2016)

The Role of Radiotherapy in Endometrial Cancer: Current Evidence and Trends
por: Creutzberg, Carien L., et al.
Publicado: (2011)

Incorporation of molecular characteristics into endometrial cancer management
por: Vermij, Lisa, et al.
Publicado: (2019)

Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
por: Church, David N., et al.
Publicado: (2014)

Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer
por: Horeweg, Nanda, et al.
Publicado: (2023)

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up
por: Colombo, Nicoletta, et al.
Publicado: (2016)

POLE proofreading mutation, immune response and prognosis in endometrial cancer
por: van Gool, Inge C., et al.
Publicado: (2015)

Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
por: van den Heerik, Anne Sophie V M, et al.
Publicado: (2021)

Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer
por: Post, Cathalijne C B, et al.
Publicado: (2021)

HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes
por: Vermij, Lisa, et al.
Publicado: (2020)

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition
por: Eggink, Florine A., et al.
Publicado: (2016)

Multidimensional intratumour heterogeneity in neuroblastoma
por: von Stedingk, Kristoffer, et al.
Publicado: (2019)

Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas
por: León‐Castillo, Alicia, et al.
Publicado: (2020)

Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer
por: Peters, Elke E M, et al.
Publicado: (2019)

Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
por: Vermij, Lisa, et al.
Publicado: (2023)

Tertiary lymphoid structures critical for prognosis in endometrial cancer patients
por: Horeweg, Nanda, et al.
Publicado: (2022)

QPOLE: A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction
por: Van den Heerik, Anne Sophie V.M., et al.
Publicado: (2023)

Folate receptor-α targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study
por: Boogerd, Leonora S.F., et al.
Publicado: (2017)

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
por: León-Castillo, Alicia, et al.
Publicado: (2020)

Breast Carcinoma, Intratumour Heterogeneity and Histological Grading, Using Geostatistics
por: Sharifi‐Salamatian, Vénus, et al.
Publicado: (2000)

popFBA: tackling intratumour heterogeneity with Flux Balance Analysis
por: Damiani, Chiara, et al.
Publicado: (2017)

Intratumour heterogeneity in microRNAs expression regulates glioblastoma metabolism
por: Alfardus, Huda, et al.
Publicado: (2021)

The roles of intratumour heterogeneity in the biology and treatment of pancreatic ductal adenocarcinoma
por: Evan, Theodore, et al.
Publicado: (2022)

Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
por: Jamieson, Amy, et al.
Publicado: (2023)

Interpretation of somatic POLE mutations in endometrial carcinoma
por: León‐Castillo, Alicia, et al.
Publicado: (2020)

Leveraging single‐cell sequencing to unravel intratumour heterogeneity and tumour evolution in human cancers
por: Bowes, Amy L, et al.
Publicado: (2022)

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial
por: Vermij, Lisa, et al.
Publicado: (2022)

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
por: Wortman, B. G., et al.
Publicado: (2018)

Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response
por: Temko, Daniel, et al.
Publicado: (2018)

Intratumour heterogeneity in the uptake of macromolecular therapeutic agents in human melanoma xenografts
por: Graff, B A, et al.
Publicado: (2003)

Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives
por: Saunders, Nicholas A, et al.
Publicado: (2012)

Plasticity and intratumoural heterogeneity of cell surface antigen expression in breast cancer
por: Remšík, Ján, et al.
Publicado: (2018)

Immunophenotypic features of dedifferentiated skull base chordoma: An insight into the intratumoural heterogeneity
por: Batista, Kelvin Manuel Piña, et al.
Publicado: (2017)

Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma
por: Akgül, Seçkin, et al.
Publicado: (2019)

Microsatellite instability and intratumoural heterogeneity in 100 right-sided sporadic colon carcinomas
por: Chapusot, C, et al.
Publicado: (2002)

Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity
por: Hoefflin, Rouven, et al.
Publicado: (2016)

Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma
por: Nguyen, Phuong H. D., et al.
Publicado: (2021)

Study on the Value of DCE-MRI in Differentiating Glossitis and Tongue Cancer and the Intratumour Heterogeneity
por: Liu, Fenghai, et al.
Publicado: (2021)

MYTH: An algorithm to score intratumour heterogeneity based on alterations of DNA methylation profiles
por: Liu, Qian, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2afpa1ochpb5o0bugc0natcvsu